BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 18720471)

  • 1. MAGI2 genetic variation and inflammatory bowel disease.
    McGovern DP; Taylor KD; Landers C; Derkowski C; Dutridge D; Dubinsky M; Ippoliti A; Vasiliauskas E; Mei L; Mengesha E; King L; Pressman S; Targan SR; Rotter JI
    Inflamm Bowel Dis; 2009 Jan; 15(1):75-83. PubMed ID: 18720471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype.
    Zholudev A; Zurakowski D; Young W; Leichtner A; Bousvaros A
    Am J Gastroenterol; 2004 Nov; 99(11):2235-41. PubMed ID: 15555007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concordance in Anti-OmpC and Anti-I2 Indicate the Influence of Genetic Predisposition: Results of a European Study of Twins with Crohn's Disease.
    Amcoff K; Joossens M; Pierik MJ; Jonkers D; Bohr J; Joossens S; Romberg-Camps M; Nyhlin N; Wickbom A; Rutgeerts PJ; Tysk C; Bodin L; Colombel JF; Vermeire S; Halfvarson J
    J Crohns Colitis; 2016 Jun; 10(6):695-702. PubMed ID: 26818662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting tissular immune response improves diagnostic performance of anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease.
    Bertin D; Grimaud JC; Lesavre N; Benelmouloud C; Desjeux A; Garcia S; Desplat-Jégo S
    PLoS One; 2013; 8(11):e80433. PubMed ID: 24303014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective comparative study of ASCA and pANCA in Chinese and Caucasian IBD patients.
    Lawrance IC; Murray K; Hall A; Sung JJ; Leong R
    Am J Gastroenterol; 2004 Nov; 99(11):2186-94. PubMed ID: 15555001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies to Escherichia coli outer membrane porin C in the absence of anti-Saccharomyces cerevisiae antibodies and anti-neutrophil cytoplasmic antibodies are an unreliable marker of Crohn disease and ulcerative colitis.
    Davis MK; Andres JM; Jolley CD; Novak DA; Haafiz AB; González-Peralta RP
    J Pediatr Gastroenterol Nutr; 2007 Oct; 45(4):409-13. PubMed ID: 18030205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined serological, genetic, and inflammatory markers differentiate non-IBD, Crohn's disease, and ulcerative colitis patients.
    Plevy S; Silverberg MS; Lockton S; Stockfisch T; Croner L; Stachelski J; Brown M; Triggs C; Chuang E; Princen F; Singh S
    Inflamm Bowel Dis; 2013 May; 19(6):1139-48. PubMed ID: 23518807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Anti-glycan Antibodies and Inflammatory Bowel Disease Course.
    Paul S; Boschetti G; Rinaudo-Gaujous M; Moreau A; Del Tedesco E; Bonneau J; Presles E; Mounsef F; Clavel L; Genin C; Flourié B; Phelip JM; Nancey S; Roblin X
    J Crohns Colitis; 2015 Jun; 9(6):445-51. PubMed ID: 25895876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations.
    Walker LJ; Aldhous MC; Drummond HE; Smith BR; Nimmo ER; Arnott ID; Satsangi J
    Clin Exp Immunol; 2004 Mar; 135(3):490-6. PubMed ID: 15008984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher titers of anti-Saccharomyces cerevisiae antibodies IgA and IgG are associated with more aggressive phenotypes in Romanian patients with Crohn's disease.
    Gologan S; Iacob R; Preda C; Vadan R; Cotruta B; Catuneanu AM; Iacob S; Constantinescu I; Gheorghe L; Iobagiu S; Gheorghe C; Diculescu M
    J Gastrointestin Liver Dis; 2012 Mar; 21(1):39-44. PubMed ID: 22457858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort.
    Papp M; Altorjay I; Dotan N; Palatka K; Foldi I; Tumpek J; Sipka S; Udvardy M; Dinya T; Lakatos L; Kovacs A; Molnar T; Tulassay Z; Miheller P; Norman GL; Szamosi T; Papp J; ; Lakatos PL
    Am J Gastroenterol; 2008 Mar; 103(3):665-81. PubMed ID: 18047543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients.
    Papp M; Altorjay I; Norman GL; Shums Z; Palatka K; Vitalis Z; Foldi I; Lakos G; Tumpek J; Udvardy ML; Harsfalvi J; Fischer S; Lakatos L; Kovacs A; Bene L; Molnar T; Tulassay Z; Miheller P; Veres G; Papp J; ; Lakatos PL
    Inflamm Bowel Dis; 2007 Aug; 13(8):984-92. PubMed ID: 17417801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Saccharomyces cerevisiae antibodies status is associated with oral involvement and disease severity in Crohn disease.
    Russell RK; Ip B; Aldhous MC; MacDougall M; Drummond HE; Arnott ID; Gillett PM; McGrogan P; Weaver LT; Bisset WM; Mahdi G; Wilson DC; Satsangi J
    J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):161-7. PubMed ID: 19179877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of inflammatory bowel disease serology in patients with indeterminate colitis.
    Sura SP; Ahmed A; Cheifetz AS; Moss AC
    J Clin Gastroenterol; 2014 Apr; 48(4):351-5. PubMed ID: 24492405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimising the diagnostic value of anti-Saccharomyces cerevisiae-antibodies (ASCA) in Crohn's disease.
    Klebl FH; Bataille F; Hofstädter F; Herfarth H; Schölmerich J; Rogler G
    Int J Colorectal Dis; 2004 Jul; 19(4):319-24. PubMed ID: 14745572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serological markers predict inflammatory bowel disease years before the diagnosis.
    van Schaik FD; Oldenburg B; Hart AR; Siersema PD; Lindgren S; Grip O; Teucher B; Kaaks R; Bergmann MM; Boeing H; Carbonnel F; Jantchou P; Boutron-Ruault MC; Tjønneland A; Olsen A; Crowe FL; Peeters PH; van Oijen MG; Bueno-de-Mesquita HB
    Gut; 2013 May; 62(5):683-8. PubMed ID: 22842615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic role and clinical correlates of anti-Saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel diseases.
    Saibeni S; Folli C; de Franchis R; Borsi G; Vecchi M
    Dig Liver Dis; 2003 Dec; 35(12):862-8. PubMed ID: 14703881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of serum antibodies in patients suspected of having inflammatory bowel disease.
    Jaskowski TD; Litwin CM; Hill HR
    Clin Vaccine Immunol; 2006 Jun; 13(6):655-60. PubMed ID: 16760323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serological antibodies and surgery in a population-based inception cohort of Crohn's disease patients - the IBSEN study.
    Kristensen VA; Cvancarova M; Høivik ML; Moum B; Vatn MH
    Scand J Gastroenterol; 2020 Apr; 55(4):436-441. PubMed ID: 32252542
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-Saccharomyces cerevisiae antibody does not differentiate between Crohn's disease and intestinal tuberculosis.
    Makharia GK; Sachdev V; Gupta R; Lal S; Pandey RM
    Dig Dis Sci; 2007 Jan; 52(1):33-9. PubMed ID: 17160471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.